Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
How effective is the flu shot this year? New report shows promising results - 2Mechanical Sidekick d: A Survey of \Elements and Execution d\ Cell phone
- 3What to expect from the planets in 2026 — key dates and sky events
- 4Putin, Netanyahu discuss Middle East in phone call, Kremlin says
- 5When Would it be a good idea for you to Look for Help from a Criminal Legal counselor?
- FDA official discusses potential link between COVID-19 vaccines and pediatric deaths
- Getting Your Youngsters' Future: Grasping Legacy Regulations
- Al-Sharaa denies he called for 80% of Syrians to return from Germany
- Vote in favor of the Top Vegetable for Senior
- If evolution is real, then why isn’t it happening now? An anthropologist explains that humans actually are still evolving
- The beauty advent calendar boom is here. Sephora kids are all in.
- James Webb Space Telescope watches 'Jekyll and Hyde' galaxy shapeshift into a cosmic monster
- The most effective method to Distinguish the Best Material Organization in Your Space
- One third of Spanish pork export certificates blocked since swine fever outbreak, minister says
